Search Results - "Wirth, MP"

Prospective Randomized Trial Comparing Flutamide as Adjuvant Treatment versus Observation after Radical Prostatectomy for Locally Advanced, Lymph Node-Negative Prostate Cancer by Wirth, Manfred P., Weissbach, Lothar, Marx, Franz-Josef, Heckl, Wilhelm, Jellinghaus, Wilfried, Riedmiller, Hubertus, Noack, Birgit, Hinke, Axel, Froehner, Michael

“…Objective: To assess the efficacy and the tolerability of flutamide as adjuvant treatment after radical prostatectomy for locally advanced, lymph node-negative…”
Get full text

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer by MCLEOD, DAVID G., IVERSEN, PETER, SEE, WILLIAM A., MORRIS, THOMAS, ARMSTRONG, JON, WIRTH, MANFRED P.

“…OBJECTIVE To evaluate, in the ongoing Early Prostate Cancer (EPC) trial programme, the efficacy and tolerability of bicalutamide 150 mg once daily in addition…”
Get full text

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years by Wirth, Manfred P, See, William A, McLeod, David G, Iversen, Peter, Morris, Tom, Carroll, Kevin

“…We evaluated the efficacy and tolerability of 150 mg bicalutamide daily given in addition to standard care, in patients with localized or locally advanced…”
Get more information

Peri‐operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score‐weighted European multicentre study by Vetterlein, Malte W., Gild, Philipp, Kluth, Luis A., Seisen, Thomas, Gierth, Michael, Fritsche, Hans‐Martin, Burger, Maximilian, Protzel, Chris, Hakenberg, Oliver W., Landenberg, Nicolas, Roghmann, Florian, Noldus, Joachim, Nuhn, Philipp, Pycha, Armin, Rink, Michael, Chun, Felix K.‐H., May, Matthias, Fisch, Margit, Aziz, Atiqullah, Bartsch, G, Bolenz, C, Brookman‐May, S, Buchner, A, Durschnabel, M, Ellinger, J, Froehner, M, Georgieva, G, Gilfrich, C, Gördük, M, Grimm, MO, Hadaschik, B, Haferkamp, A, Hartmann, F, Herrmann, E, Hertle, L, Hohenfellner, M, Janetschek, G, Keck, B, Kraischits, N, Krausse, A, Lusuardi, L, Martini, T, Michel, MS, Moritz, R, Müller, SC, Novotny, V, Pahernik, S, Palisaar, RJ, Ponholzer, A, Roigas, J, Schmid, M, Schramek, P, Seitz, C, Sikic, D, Stief, CG, Syring, I, Traumann, M, Vallo, S, Wagenlehner, FM, Weidner, W, Wirth, MP, Wullich, B

“…Objectives To evaluate the effect of peri‐operative blood transfusion (PBT) on recurrence‐free survival, overall survival, cancer‐specific mortality and…”
Get full text

Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients by Williams, Stephen B., Kamat, Ashish M., Chamie, Karim, Froehner, Michael, Wirth, Manfred P., Wiklund, Peter N., Black, Peter C., Steinberg, Gary D., Boorjian, Stephen A., Daneshmand, Sia, Goebell, Peter J., Pohar, Kamal S., Shariat, Shahrokh F., Thalmann, George N.

“…Radical cystectomy continues to be associated with a significant risk of morbidity and all-cause mortality (ACM). Practice pattern data demonstrating underuse…”
Get full text

Ferromagnetic filled carbon nanotubes and nanoparticles: synthesis and lipid-mediated delivery into human tumor cells by Mönch, I., Meye, A., Leonhardt, A., Krämer, K., Kozhuharova, R., Gemming, T., Wirth, M.P., Büchner, B.

“…We describe the synthesis and the properties of Fe-filled multi-walled carbon nanotubes (MWNTs) and nanoparticles (NP) produced by chemical vapor deposition…”
Get full text

Antisense-mediated hTERT Inhibition Specifically Reduces the Growth of Human Bladder Cancer Cells by KRAEMER, Kai, FUESSEL, Susanne, SCHMIDT, Uta, KOTZSCH, Matthias, SCHWENZER, Bernd, WIRTH, Manfred P, MEYE, Axel

“…Purpose: The expression of human telomerase reverse transcriptase (hTERT) is associated with cellular aging and tumorigenesis. It was found in nearly all…”
Get full text

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program by See, William A, Wirth, Manfred P, McLeod, David G, Iversen, Peter, Klimberg, Ira, Gleason, Donald, Chodak, Gerald, Montie, James, Tyrrell, Chris, Wallace, D M A, Delaere, Karl P J, Vaage, Sigmund, Tammela, Teuvo L J, Lukkarinen, Olavi, Persson, Bo-Eric, Carroll, Kevin, Kolvenbag, Geert J C M

“…We determine the efficacy and tolerability of bicalutamide as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with…”
Get more information

Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA by Fuessel, Susanne, Herrmann, Jana, Ning, Shuangli, Kotzsch, Matthias, Kraemer, Kai, Schmidt, Uta, Hakenberg, Oliver W., Wirth, Manfred P., Meye, Axel

“…Survivin is known to be overexpressed in numerous tumor types including human bladder cancer and to cause resistance to radiation and chemotherapy. Therefore,…”
Get full text

siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth by Ning, Shuangli, Fuessel, Susanne, Kotzsch, Matthias, Kraemer, Kai, Kappler, Matthias, Schmidt, Uta, Taubert, Helge, Wirth, Manfred P, Meye, Axel

“…Survivin is recognized as a general target in cancer therapy because of its selective overexpression in the majority of tumors. In bladder cancer (BCa), its…”
Get more information

Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme by Tyrrell, Chris J, Payne, Heather, See, William A, McLeod, David G, Wirth, Manfred P, Iversen, Peter, Armstrong, Jon, Morris, Clive

“…The ongoing Early Prostate Cancer (EPC) programme is assessing bicalutamide ('Casodex') 150 mg, either alone or as adjuvant to treatment of curative intent, in…”
Get full text

Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy by Froehner, Michael, Koch, Rainer, Litz, Rainer, Heller, Axel, Oehlschlaeger, Sven, Wirth, Manfred P

“…To compare the American Society of Anesthesiologists Physical Status (ASA) classification with the Charlson score in the radical prostatectomy setting. The ASA…”
Get full text

Treating renal cell cancer in the elderly by BERDJIS, NAVID, HAKENBERG, OLIVER W., NOVOTNY, VLADIMIR, FROEHNER, MICHAEL, WIRTH, MANFRED P.

“…OBJECTIVE To determine whether age and comorbidity are predictors of peri‐operative complications and/or mortality in surgery for renal cell cancer in a…”
Get full text

Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR by Fuessel, Susanne, Sickert, Denise, Meye, Axel, Klenk, Ulrich, Schmidt, Uta, Schmitz, Marc, Rost, Anne-Katrin, Weigle, Bernd, Kiessling, Andrea, Wirth, Manfred P

“…The identification of new diagnostic markers and potential treatment targets for prostate carcinoma (PCa) necessitates the evaluation of expression patterns in…”
Get more information

Bladder wall thickness in normal adults and men with mild lower urinary tract symptoms and benign prostatic enlargement by Hakenberg, Oliver W., Linne, Clemens, Manseck, Andreas, Wirth, Manfred P.

“…There is evidence that increased bladder wall thickness can be a useful parameter in the evaluation of men with clinical benign prostatic hyperplasia (BPH)…”
Get full text

Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma by Schrodter, Steffen, Hakenberg, Oliver W, Manseck, Andreas, Leike, Steffen, Wirth, Manfred P

“…Isolated local recurrences after radical nephrectomy for renal cell carcinoma occur in 2% to 3% of cases. Today local recurrences can be detected at an early…”
Get more information

Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction by Wuest, Melinda, Hecht, Juliane, Christ, Torsten, Braeter, Manfred, Schoeberl, Christian, Hakenberg, Oliver W, Wirth, Manfred P, Ravens, Ursula

“…1 Besides its antimuscarinic effects, propiverine may possess an additional mode of action. We compared the effects of propiverine, three of its metabolites…”
Get full text

Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients by Kiessling, Andrea, Schmitz, Marc, Stevanovic, Stefan, Weigle, Bernd, Hölig, Kristina, Füssel, Monika, Füssel, Susanne, Meye, Axel, Wirth, Manfred P., Rieber, Ernst Peter

“…Identification of TAAs recognized by CD8+ CTLs paved the way for new concepts in cancer therapy. In view of the heterogeneity of tumors and their diverse…”
Get full text

Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma by Weber, Thomas, Meinhardt, Matthias, Zastrow, Stefan, Wienke, Andreas, Erdmann, Kati, Hofmann, Jörg, Fuessel, Susanne, Wirth, Manfred P

“…To enhance prognostic information of protein biomarkers for clear cell renal cell carcinomas (ccRCCs), we analyzed them within prognostic groups of ccRCC…”
Get full text

Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells by Fuessel, Susanne, Kueppers, Bernd, Ning, Shuangli, Kotzsch, Matthias, Kraemer, Kai, Schmidt, Uta, Meye, Axel, Wirth, Manfred P

“…The rather poor responses to conventional treatment for bladder cancer (BCa) require novel, specific therapy approaches. The down-regulation of BCa associated…”
Get more information